Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan Licenses DrugTarget Database to Undisclosed Pharma

NEW YORK, Aug. 23 (GenomeWeb News) - LifeSpan BioSciences said today that it has licensed its DrugTarget database to an undisclosed pharmaceutical company, marking the 50th database license the company has issued.

 

According to the company, the database contains proprietary human protein localization data for drug targets in eight gene families, including G protein-coupled receptors, nuclear hormone receptors, kinases, ion channels, phosphatases, proteases, phosphodiesterases, and transporters.

 

Under the new licensing agreement, the subscriber will nominate 50 additional genes for study and inclusion in the expanded database over a two-year period. It already includes 822 immunohistochemistry reports with localization information on more than 400 potential drug target genes selected by subscribers, said LifeSpan. The expanded database will include ion channels, secreted proteins, phosphatases, and other families of genes.

 

Additional terms of the license were not disclosed.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.